Translational Immunology Innovations
Translational
immunology is the process by which researchers use immunological discoveries to develop practical solutions for human problems. Examples include the
development of vaccines against infectious diseases or the engineering of new types of
drugs to treat inflammatory disorders.
Translational research is defined as research that uses findings from basic science studies for practical applications that enhance
health and well-being both in humans and animals.
CD8 T-cells are important for protection against a plethora of different pathogens and are also capable of killing cancerous cells. In contrast, dysregulated CD8 T-cell
immunity can have devastating effects, for example
autoimmunity and graft rejection. Professor Linda Wooldridge leads the research aimed at understanding the basic
immunology of the CD8 T-cell response and translates the groups’ findings to improve our understanding of the mechanisms that underlie CD8 T-cell mediated disease and the development of novel therapeutic strategies. As such, the group has active projects that span three different areas:
· Understanding the basic mechanisms involved in CD8 T-cell activation
· Understanding the
pathogenesis of common CD8 T-cell mediated disease
· Translation for the development of novel therapeutic strategies
High Impact List of Articles
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging approaches to the treatment of ventilator-associated pneumonia
B Mourvillier1, L Berra & J Wiener-Kronish
Review: Clinical Trail Outcomes: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
Trial discontinuation: lessons for future trial design?
Veerle JAA Nuij, Colin J de Haar & C Janneke van der Woude
Clinical Trail Methodology: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
-
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Andrew J Weickhardt, D Ross Camidge
Review Article: Clinical Investigation
Relevant Topics in Clinical